The dangerous form of the malaria parasite which cannot be killed with the main anti-malaria drugs emerged in Cambodia but has since spread through parts of Thailand, Laos and has arrived in southern Vietnam.
Researchers at Oxford Tropical Medicine Research Unit in Bangkok in a letter, published in The Lancet Infectious Diseases, detail the "recent sinister development" that has seen resistance to the drug artemisinin emerge.
The first choice treatment for malaria is artemisinin in combination with piperaquine. But as artemisinin has become less effective, the parasite has now evolved to resist piperaquine too, researchers said.
There have now been alarming rates of failure. The treatment was failing around a third of the time in Vietnam while in some regions of Cambodia the failure rate was closer to 60 per cent, Dondorp said.
About 212 million people are infected with malaria each year. It is caused by a parasite that is spread by blood- sucking mosquitoes and is a major killer of children.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
